Aandeel 2696 SHANGHAI HENLIUS BIOTECH, INC.
Toevoegen aan een lijst
Om deze functie te gebruiken moet u een klant of lid zijn.
InloggenRegistreren

Andere talen Shanghai Henlius Biotech, Inc.

Aandelen

2696

CNE100003N76

Beurs gesloten - Hong Kong S.E.
Andere beurzen
 10:08:06 30-04-2024 		Variatie 5 dagen Verschil t.o.v. 1 jan (%)
16,32 HKD -2,74% Intraday-grafiek van Shanghai Henlius Biotech, Inc. +6,95% +17,41%
26/04 Kankermedicijn van Shanghai Henlius Biotech krijgt goedkeuring van Amerikaanse FDA MT
24/04 Shanghai Henlius Biotech doseert 1e patiënt in klinische studie naar fibrosemedicijn in China MT

Andere talen

Zoeken op
Resultaten bekijken
Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!
Gratis inschrijven
Henlius Biotech Logs 1.35 Billion Yuan Revenue in Q1
Henlius maintained a positive momentum of development in Q1 2024, with impressive performances by core products
Shanghai Henlius Biotech's Cancer Drug Gets the Nod from US FDA
Shanghai Henlius Biotech Doses 1st Patient in Fibrosis Drug Clinical Study in China
Shanghai Henlius Biotech, Inc. Announces First Subject Dosed in Phase 1 Clinical Study in Healthy Subjects of HLX6018 in Mainland China
Shanghai Henlius Biotech, Inc. - IND Application for the Clinical Trial of Novel Anti-TIGIT Fc Fusion Protein HLX53 in Combination with HANSIZHUANG Plus HANBEITAI Approved by NMPA
Henlius Releases 2023 ESG Report: Pursuing Sustainable Development with Patient-centricity
Henlius Biotech Gets Clearance for China Clinical Trial of Carcinoma Drug
Shanghai Henlius Biotech, Inc. Announces Application for the Clinical Trial of HLX53 (Anti-TIGIT Fc Fusion Protein) in Combination with HANSIZHUANG (Serplulimab Injection) and HANBEITAI (Bevacizumab Injection) for the First-Line Treatment of Local Advanced or Metastatic Hepatocellular Carcinoma was Approved by the National Medical Products Administration
Shanghai Henlius Biotech Denosumab Biosimilar HLX14 Meets Endpoint
Shanghai Henlius Biotech, Inc Announces Phase 3 Comparative Clinical Study of Prolia® and Xgeva® Biosimilar Candidate HLX14 Met Primary Endpoints
Phase 3 Trial of Shanghai Henlius Biotech’s Osteoporosis Drug Meets Primary Study Endpoints
Shanghai Henlius Biotech, Inc. Announces International Multi-Centre Phase 3 Clinical Study of Biosimilar of Denosumab HLX14 for Treatment of Osteoporosis in Postmenopausal Women at High Risk for Fracture has Met Primary Study Endpoints
Shanghai Henlius Biotech Turns to Profit in 2023
Shanghai Henlius Biotech, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Henlius Biotech Doses First Patient in Phase 1 Clinical Trial of Cancer Drug
Shanghai Henlius Biotech, Inc. Announces the First Patient Has Been Dosed in A Phase 1 Clinical Study of Hlx42 for Injection
Shanghai Henlius Biotech's Fibrosis Drug Gets Chinese Authorities' Nod for Clinical Trials
Shanghai Henlius Biotech, Inc. Announces Application for Clinical Trial of HLX6018 (Recombinant Anti-GARP/TGF-1 Humanised Monoclonal Antibody Injection) Approved by the National Medical Products Administration
Shanghai Henlius Biotech Expects Record Full-Year Profit
Geen resultaten voor deze zoekopdracht
Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Filters

Zoeken op

Datum van publicatie

Sinds de

Tot

  1. Beurs
  2. Aandelen
  3. Koers 2696
  4. Nieuws Shanghai Henlius Biotech, Inc.
  5. Andere talen